Developing Melflufen (Ygalo): alkylating peptide in class of Peptidase Enhanced Compounds targeting MM transformation process, selectively targets MM. Accelerated approval filing planned H1'20 based on ongoing Ph2 Horizon. MoA overcomes resistance mechanisms for current therapies (iMIDs), demonstrated superior efficacy vs. SOC. Presented interim data at ASH (2019) from ongoing Ph2 HORIZON study in late stage r/r MM showing ORR of ~32%. Ph 3 OCEAN study comparing Ygalo to pomalidomide in late-stage r/r MM, Ph 1/2 ANCHOR study in combo w bortezomib or daratumumab in r/r MM.
500MM - 1B
Västra Trädgårdsgatan 15
Stockholm, SE-111 53
Top 10 Holders of Oncopeptides AB
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by